Is the mass screening for neuroblastoma ineffective?

Area of Science:

• Pediatric Oncology
• Screening Program Evaluation

Background:

• A recent study by Schilling et al. (2002) questioned the effectiveness of mass screening for neuroblastoma in 12-month-old children.
• This reevaluation addresses methodological issues in the original study that may have led to an inaccurate conclusion.

Purpose of the Study:

• To reestimate the effectiveness of mass screening for neuroblastoma in 12-month-old children using data from Schilling et al. (2002).
• To identify and correct for biases in the original study's methodology.

Main Methods:

• Utilized data from Schilling et al. (2002), comparing "control area" subjects with "non-participants" for bias assessment.
• Reanalyzed the calculation of the "screened group" incidence by separating false negatives and true positives.
• Compared stage 4 neuroblastoma incidence and mortality between false negatives and non-participants.

Main Results:

• The use of "control area" subjects as controls underestimated screening effectiveness by approximately 25%.
• Combining false negatives and true positives inflated "screened group" incidence, further underestimating effectiveness.
• Stage 4 neuroblastoma incidence was 40% lower in non-participants compared to false negatives, with lower mortality.
• An estimated 40% of true positives represent spontaneous regression cases.

Conclusions:

• The mass screening for neuroblastoma targeting 12-month-old children demonstrates effectiveness when analyzed with corrected methodologies.
• The revised findings suggest better outcomes than Japanese screening programs, supporting the value of this screening approach.